Skip to content

Cumulative live birth rates after cleavage-stage versus blastocyst-stage embryo transfer: A multicenter, prospective, randomized controlled trial

Cumulative live birth rates after cleavage-stage versus blastocyst-stage embryo transfer: A multicenter, prospective, randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-ICR-15006184
Enrollment
Unknown
Registered
2015-03-26
Start date
2018-09-09
Completion date
Unknown
Last updated
2018-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

blastocyst transfer group:single blastocyst transfer
cleavage-stage embryo transfer group:Single cleavage-stage embryo transfer

Sponsors

The first affiliated hospital of Nanjing Medical University/Jiangsu province's hosptial; Center for Reproductive Medicine, Shandong University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Women aged 20 to 40 years; 2. Women with the number of transferrable cleavage embryos = 4; 3. Women undergoing their first or second cycle of IVF or ICSI.

Exclusion criteria

Exclusion criteria: 1. Women who have been diagnosed with uterine abnormalities (confirmed by three-dimensional ultrasonography or hysteroscopy), including malformed uterus (uterus unicornis, septate uterus or duplex uterus), submucous myoma, or intrauterine adhesion; 2. Women who plan to undergo In Vitro Maturation (IVM); 3. Women who plan to undergo Preimplantation Genetic Diagnosis (PGD) /Preimplantation Genetic Screening (PGS); 4. Women who have untreated severe hydrosalpinx (proved by ultrasound or Hysterosalpingogram); 5. Women who have experienced recurrent spontaneous abortions, defined as 2 or more previous pregnancy losses; 6. Women who have been developed a freeze-all treatment plan for purpose of subsequent surgery, such as sphincterectomy due to hydrosalpinx after oocytes retrieval; 7. Women with contraindications to assisted reproductive technology and/or pregnancy, such as uncontrolled hypertension, symptomatic heart diseases, uncontrolled diabetes, undiagnosed liver disease or dysfunction (based on serum liver enzyme test results), undiagnosed renal disease or abnormal renal function, severe anemia, history of deep venous thrombosis, pulmonary embolus or cerebrovascular accident, history of or suspicious for cancer, undiagnosed vaginal bleeding.

Design outcomes

Primary

MeasureTime frame
Cumulative Birth Rate per patient until the first live birth from one initiating oocyte retrieval cycle;

Secondary

MeasureTime frame
biochemical pregnancy rate;clinical pregnancy rate;implantation rate;cumulative clinical pregnancy rate;ongoing pregnancy rate;pregnancy loss rate;live birth rate;Birth weight;sex ratio;moderate or severe OHSS rate;ectopic pregnancy rate;multiple pregnancy rate;incidence of obstetric and perinatal complications;

Countries

China

Contacts

Public ContactJiayin Liu, Zi-jiang Chen

The First Affiliated Hospital of Nanjing Medical University/Jiangsu Province's Hospital

jyliu_nj@126.com+86 025 68302608

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026